, Volume 73, Issue 13, pp 1395–1403

The Optimal Management of Follicular Lymphoma: An Evolving Field

Therapy in Practice


Follicular lymphoma consists of a heterogeneous group of diseases that can vary dramatically in clinical course. As with other indolent lymphomas, follicular lymphoma is felt to be highly treatable, but ultimately incurable. The appropriate management of this disease ranges from close observation to chemoimmunotherapy based on presenting symptoms and comorbidities. In this article, we focus on the optimal management of follicular lymphoma, including prognostication, indications for treatment, and current treatment options. While a number of front-line chemoimmunotherapy options exist, R-CHOP (rituximab, cyclophosphamide, vincristine, prednisone) and BR (bendamustine, rituximab) tend to be favored due to efficacy and tolerability. Post-induction options include maintenance rituximab and radioimmunotherapy, but neither has demonstrated an overall survival benefit. In relapsed disease, patients can receive an alternative chemoimmunotherapy regimen or radioimmunotherapy, or participate in a clinical trial. There are a number of new biologic targeted therapies with promising activity in follicular lymphoma that have the potential to change our approach to this disease.


  1. 1.
    López-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93(9):3081–7.PubMedGoogle Scholar
  2. 2.
    Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16(7):2332–8.PubMedGoogle Scholar
  5. 5.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11–6.PubMedGoogle Scholar
  8. 8.
    Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110–7.PubMedGoogle Scholar
  9. 9.
    Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Cheson BD. Waiting is the hardest part. J Clin Oncol. 2012;30(31):3781–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National Lympho Care Study. J Clin Oncol. 2012;30(27):3368–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17(6):1851–7.PubMedGoogle Scholar
  15. 15.
    Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79(9):493–500.PubMedCrossRefGoogle Scholar
  16. 16.
    Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23(9):2380–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Federico M, Luminari S, Dondi A, et al. R-CVP Versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Nastoupil L, Sinha R, Byrtek M et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma used in the United States. Blood (ASH Annual Meeting Abstracts). 2011;118 (Abstract 97).Google Scholar
  19. 19.
    Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade NHL. Anticancer Drugs. 2001;12(9):725–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent, and transformed NHL. J Clin Oncol. 2008;26(2):204–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Kahl B, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell NHL. Cancer. 2010;116(1):106–14.PubMedGoogle Scholar
  22. 22.
    Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(15):3383–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(27):4473–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (early online publication) 2013. doi:10.1016/S0140-6736(12)61763-2Cite.
  25. 25.
    Flinn I, Van der Jagt R, Kahl B, et al. An open-label, randomized study of bendamustine and rituximab compared with rituximab, cyclophosphamide, vincristine, and prednisone or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma or mantle cell lymphoma: the Bright study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 902).Google Scholar
  26. 26.
    Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Friedberg J, Vose J, Kelly J, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell NHL. Blood. 2011;117(10):2807–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Ardeshna KM, Smith P, Qian W, et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis. Blood (ASH annual meeting abstracts). 2010;116 (Abstract 6).Google Scholar
  30. 30.
    Kahl B, Hong F, Williams M, et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood (ASH annual meeting abstracts). 2011;118 (Abstract 6).Google Scholar
  31. 31.
    Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Witzig T, Linn I, Gordon L, et al. Treatment with ibritumomab tiuxetan radiotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(15):3262–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaminski M, Zelenetz A, Press O, et al. Pivotal study of iodine-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19(19):3918–28.PubMedGoogle Scholar
  34. 34.
    Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with Yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine–tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314–20.PubMedCrossRefGoogle Scholar
  36. 36.
  37. 37.
    Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105(12):4576–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol. 2010;28(18):3035–41.PubMedCrossRefGoogle Scholar
  39. 39.
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.PubMedGoogle Scholar
  40. 40.
    van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Czuczman M, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698–704.PubMedCrossRefGoogle Scholar
  43. 43.
    Fowler N, Kahanic S, Forero A, et al. Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin’s lymphoma. Blood. (ASH annual meeting abstracts). 2011;118 (Abstract 778).Google Scholar
  44. 44.
    Czuczman M, Viardot A, Hess G, et al. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). J Clin Oncol. (ASCO annual meeting abstracts). 2010;28(15) (Abstract 8042).Google Scholar
  45. 45.
    Sehn L, Goy A, Offner F, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. Blood. (ASH annual meeting abstracts). 2011;118 (Abstract 269).Google Scholar
  46. 46.
    Leonard J, Coleman M, Ketas J, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21(16):3051–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Grant B, Leonard J, Johnson J, et al. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701—a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood (ASH annual meeting abstracts). 2010;116 (Abstract 427).Google Scholar
  48. 48.
    Forero A, Hamadani M, Fanale M, et al. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: results from a phase 1/2 study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 3677).Google Scholar
  49. 49.
    Goy A, Leach J, Ehmann W, et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Blood (ASH annual meeting abstracts). 2010;116 (Abstract 430).Google Scholar
  50. 50.
    Palanca-Wessels M, Flinn I, Sehn L, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Blood (ASH annual meeting abstracts). 2012;120 (Abstract 56).Google Scholar
  51. 51.
    Advani R, Lebovic D, Brunvand M, et al. A phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Blood (ASH annual meeting abstracts). 2012;120 (Abstract 59).Google Scholar
  52. 52.
    Leonard J, Jung S, Johnson J, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol. (ASCO meeting abstracts). 2012;30(15) (Abstract 8000).Google Scholar
  53. 53.
    Fowler N, Neelapu S, Hagemeister F, et al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 901).Google Scholar
  54. 54.
    Fowler N, Advani R, Sharman J, et al. The Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 156).Google Scholar
  55. 55.
    Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a phase 1 study of CAL-101, and isoform-selective inhibitor of phosphatidylinositol 3-kinase p110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. (ASH annual meeting abstracts). 2010;116 (Abstract 1777).Google Scholar
  56. 56.
    Fowler N, de Vos S, Schreeder M, et al. Combinations of the phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: results from a phase I study. Blood. (ASH annual meeting abstracts). 2012;120 (Abstract 3645).Google Scholar
  57. 57.
    Davids M, Roberts A, Anderson M, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood. (ASH annual meeting abstracts). 2012;120 (Abstract 304).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of Hematology-Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University HospitalWashingtonUSA

Personalised recommendations